reports
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targe...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver....
Director/PDMR Shareholding
Director/PDMR Shareholding TORONTO, ONTARIO, April 16, 2024 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Director/PDMR Shareholding - Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ONTARIO – April 16, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ) announces that on April 15, 2024, it was informed that Livermore Partners LLC, a company in which David Neuhauser, Non-Executive Director of Amaroq Minerals, is Managing Director, acquired a total of 19,200 common shares of no par value in the Company. This ...
Edison issues review on Tetragon Financial Group (TFG): FY23 growth dr...
Edison Investment Research Limited Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors 16-Apr-2024 / 12:07 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 16 April 2024 Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 pe...
Divfex Berhad: 1 director
A director at Divfex Berhad sold 4,870,000 shares at 0.133MYR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
KRM22: 1 director
A director at KRM22 bought 100,000 shares at 25p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
Zhongzhi Pharmaceutical Holdings Limited: 1 director
A director at Zhongzhi Pharmaceutical Holdings Limited bought 2,259,000 shares at 1.170HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. “We are...
EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to De...
Issuer: CureVac / Key word(s): Alliance CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines 16.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic...
EQS-News: CureVac und MD Anderson gehen strategische Kooperation zur E...
Emittent / Herausgeber: CureVac / Schlagwort(e): Kooperation CureVac und MD Anderson gehen strategische Kooperation zur Entwicklung neuartiger Krebsimpfstoffe ein 16.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac und MD Anderson gehen strategische Kooperation zur Entwicklung neuartiger Krebsimpfstoffe ein Kooperation schafft starke Synergien zwischen einzigartiger mRNA-Kompetenz von CureVac und translationaler und klinischer Forschungsexpertise von MD Anderson Entwicklung neuartiger, „off-the-shelf“ ...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results fr...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p
Melco International Development: 1 director
A director at Melco International Development bought 1,200,000 shares at 5.700HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Thanh Thanh Cong - Bien Hoa : 1 director
A director at Thanh Thanh Cong - Bien Hoa sold 15,000,000 shares at 0.000VND and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Hanwha Life Insurance Co Ltd: 1 director
A director at Hanwha Life Insurance Co Ltd bought 20,000 shares at 2,640.000KRW and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Fiera Capital Corp: 1 director
A director at Fiera Capital Corp sold 61,600 shares at 7.800CAD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Nam Song Hau Trading Investing Petroleum Joint Stock Company: 1 direct...
A director at Nam Song Hau Trading Investing Petroleum Joint Stock Company sold 2,017,700 shares at 0.000VND and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
Voyager Therapeutics Announces Selection of Development Candidate for ...
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate c...
Aya Gold & Silver Announces Robust Mineral Resource Estimate at Boumad...
Aya Gold & Silver Announces Robust Mineral Resource Estimate at Boumadine MONTREAL, April 16, 2024 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce a Mineral Resource Estimate (“MRE”) prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) at its Boumadine Project in the Kingdom of Morocco. The MRE contains an Inferred Mineral Resource of 23.6 million tonnes (“Mt”) at 85 grams per tonne (“g/t”) silver (“Ag”), 2.62 g/t gold (“Au”), 2.32% zinc (“Zn”) and 0.84% l...
Aya Or & Argent annonce une robuste estimation de ressources minérales...
Aya Or & Argent annonce une robuste estimation de ressources minérales à Boumadine MONTRÉAL, 16 avr. 2024 (GLOBE NEWSWIRE) -- Aya Or & Argent Inc. (TSX : AYA; OTCQX : AYASF) (« Aya » ou la « Société ») a le plaisir d’annoncer une estimation de ressources minérales (« ERM ») préparée conformément au Règlement 43-101 sur l’information concernant les projets miniers (le « Règlement 43-101 ») sur son projet Boumadine dans le Royaume du Maroc. L’ERM fait état de ressources minérales présumées de 23,6 millions de tonnes (« Mt ») à 85 grammes par tonne (« g/t ») d’argent (« Ag »), 2,62 g/t d’or ...
Multitude SE - Managers' transactions - Kabele
Multitude SE - Managers' transactions - Kabele Multitude SE - Managers' transactions - Kabele ____________________________________________ Person subject to the notification requirementName: Kabele, KornelPosition: Other senior managerIssuer: Multitude SELEI: 74370078YLPFWHE33716 Notification type: INITIAL NOTIFICATIONReference number: 74370078YLPFWHE33716_20240416104440_131____________________________________________ Transaction date: 2024-04-15Venue not applicableInstrument type: SHAREISIN: FI4000106299Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction ...
Multitude SE - Managers' transactions - Vella
Multitude SE - Managers' transactions - Vella Multitude SE - Managers' transactions - Vella ____________________________________________ Person subject to the notification requirementName: Vella, ShaunPosition: Other senior managerIssuer: Multitude SELEI: 74370078YLPFWHE33716 Notification type: INITIAL NOTIFICATIONReference number: 74370078YLPFWHE33716_20240416104440_137____________________________________________ Transaction date: 2024-04-15Venue not applicableInstrument type: SHAREISIN: FI4000106299Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction deta...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.